港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

728.939

-15.659-2.10%

涨家数：14

跌家数：18

平家数：2

市盈率：- -

高：744.967

开：744.496

低：723.794

收：744.598

数据加载中...

上海浦东：支持进口创新药全球首发产品落地推动100个进口产品实现本地生产

心玮医疗-B盘中异动快速下挫5.02%

港股异动 | 开拓药业-B(09939.HK)盘中涨超7% 治疗中国男性脱发药物临床试验II期达到主要终点

迈博药业-B盘中异动股价大涨5.77%

《股市简讯》中国开拓药业涨7.1%，男性脱发药物二期临床试验达到主要终点

2025主动权益基金二季报新进个股TOP50：舒泰神成“新宠王”医药、信息科技、消费行业占比高

仓石基金研究院

李氏大药厂盘中异动早盘股价大跌5.00%报1.520港元

【IPO前哨】业绩连亏、现金流吃紧！景泽生物赴港IPO赌未来？

港股异动 | 云顶新耀(01952)涨超3% EVM14临床试验申请获受理为自研mRNA平台首个实现“中美双报”产品

心通医疗-B盘中异动早盘股价大涨5.69%报1.300港元

港股异动 | 康方生物(09926)早盘涨超5% 依沃西疗法一线治疗胰腺癌III期临床研究完成首例患者入组

中国抗体-B盘中异动早盘快速拉升5.56%报2.660港元

康方生物盘中异动早盘大幅上涨3.00%

港股开盘｜恒指低开0.04%，科指低开0.26%！创新药概念股普涨

老虎资讯综合

再鼎医药获Wellington Management Group LLP增持439.85万股

泰坦科技拟5585万元收购境外公司ASL；美中嘉和拟配股融资2.7亿港元丨医药早参

每日经济新闻

开拓药业-B(09939)：KX- 826 酊1.0%治疗中国成年男性雄激素脱发关键性临床试验II期阶段达到主要终点

加科思-B(01167)获一致行动人士进一步增持24万股

特朗普将自行决定5500亿美元日本对美投资的使用

“V型”反转中的基金“巨子”们

华尔街见闻

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news?page=8"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":728.93866,"timestamp":1753430886241,"preClose":744.5975,"halted":0,"volume":295989198,"delay":0,"changeRate":-0.02103,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-15.658813,"latestTime":"07-25 16:00:00","open":744.49634,"high":744.967,"low":723.794,"amount":7101826928,"amplitude":0.028435,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"pbRate":5.862148,"peRate":-36.113023,"turnoverRate":0.011111,"increases":13,"decrements":20,"flats":0,"marketCap":427345468672,"floatMarketCap":392843141040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":744.967,"amplitude":0.028435,"preClose":744.5975,"low":723.794,"pbRate":"5.862148","latestPrice":728.93866,"volume":295989198,"delay":0,"open":744.49634,"prevYearClose":331.1933,"prevWeekClose":711.682,"prevMonthClose":555.617,"prevQuarterClose":555.617,"fiveDayClose":711.682,"twentyDayClose":566.494,"sixtyDayClose":466.153,"secType":"PLATE","market":"HK","turnoverRate":0.011111,"peRate":-36.113023,"marketCap":427345468672,"floatMarketCap":392843141040,"timestamp":1753430886241,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":14,"down":18,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553201092","title":"上海浦东：支持进口创新药全球首发产品落地 推动100个进口产品实现本地生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2553201092","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553201092?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 11:09","pubTimestamp":1753326557,"startTime":"0","endTime":"0","summary":"上海市浦东新区人民政府办公室印发《浦东新区生物医药产业园区功能提升方案（2025—2027年）》。其中提出，推动外资企业延链布局。发挥外资研发中心集聚优势，支持进口创新药同步研发、同步临床、同步申报、同步上市，推动全球首发产品落地。把握跨国公司本地化生产、多产地布局等战略调整机遇，加强清单管理，持续跟踪服务，推动5个以上重点外资项目建设、100个进口产品通过多种方式实现本地生产。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/24110951943446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159992","06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2553227737","title":"心玮医疗-B盘中异动 快速下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553227737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553227737?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 10:21","pubTimestamp":1753323682,"startTime":"0","endTime":"0","summary":"2025年07月24日早盘10时21分，心玮医疗-B股票出现异动，股价急速下挫5.02%。资金方面，该股资金流入61.516万港元，流出157.792万港元。心玮医疗-B股票所在的医疗设备及用品行业中，整体涨幅为0.16%。消息层面，截至10时21分，《心玮医疗-B获Wisary Limited及关联方增持15.77万股H股股份，价值约740.71万港元》资讯为影响心玮医疗-B的重要信息。增持后，Wisary Limited最新持股数目为301.16万股股份，好仓比例由9.04%升至9.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724102123a6be9ebc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724102123a6be9ebc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06609","BK1100","BK1587","BK1574"],"gpt_icon":0},{"id":"2553222088","title":"港股异动 | 开拓药业-B(09939.HK)盘中涨超7% 治疗中国男性脱发药物临床试验II期达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2553222088","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553222088?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 10:10","pubTimestamp":1753323003,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","03347","BK1161","BK1583","BK1141","BK1515","09939","BK1576"],"gpt_icon":0},{"id":"2553783227","title":"迈博药业-B盘中异动 股价大涨5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553783227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553783227?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 10:05","pubTimestamp":1753322741,"startTime":"0","endTime":"0","summary":"2025年07月24日早盘10时05分，迈博药业-B股票出现波动，股价大幅拉升5.77%。截至发稿，该股报0.550港元/股，成交量2.4万股，换手率0.00%，振幅3.85%。迈博药业-B股票所在的生物技术行业中，整体涨幅为0.70%。迈博药业-B公司简介：迈博药业有限公司是一家主要从事癌症及自身免疫性疾病的单抗药物的研究、开发及生产的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724100541a4602c2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724100541a4602c2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02181","BK1574"],"gpt_icon":0},{"id":"2553222270","title":"《股市简讯》中国开拓药业涨7.1%，男性脱发药物二期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2553222270","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553222270?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 10:03","pubTimestamp":1753322612,"startTime":"0","endTime":"0","summary":"《股市简讯》中国开拓药业涨7.1%，男性脱发药物二期临床试验达到主要终点* 中国生物科技公司--开拓药业9939.HK周四早盘高开2.8%，随后涨幅扩大至7.1%。* 开拓药业今年迄今暴涨173.2%，同期恒生指数.HSI大幅上扬27.6%。* 恒生香港上市生物科技指数.HSHKBIO盘中一度升1.2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nL4T3TL06C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2553227010","title":"2025主动权益基金二季报新进个股TOP50：舒泰神成“新宠王”医药、信息科技、消费行业占比高","url":"https://stock-news.laohu8.com/highlight/detail?id=2553227010","media":"仓石基金研究院","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553227010?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 09:57","pubTimestamp":1753322220,"startTime":"0","endTime":"0","summary":"专题：聚焦2025基金二季报：AI、医药、新消费…根据天相投资顾问有限公司数据显示，舒泰神、四方精创、有方科技登上权益类基金新晋个股TOP50名单，从TOP50新增标的来看，基金择股逻辑呈现显著分化，且7月市场对这批“新宠”进行了严格检验。　　二季度新增TOP50凸显公募对高弹性成长股的追逐，但7月分化印证了“共识≠安全”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/original/2025-07-24/doc-infhprwz2980805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK0028","09939","300204","BK1161","BK1515","BK0046","BK0239","159938"],"gpt_icon":0},{"id":"2553517227","title":"李氏大药厂盘中异动 早盘股价大跌5.00%报1.520港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553517227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553517227?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 09:51","pubTimestamp":1753321901,"startTime":"0","endTime":"0","summary":"2025年07月24日早盘09时51分，李氏大药厂股票出现波动，股价急速下挫5.00%。截至发稿，该股报1.520港元/股，成交量5.6万股，换手率0.01%，振幅1.88%。资金方面，该股资金流入2325港元，流出7.9875万港元。最近的财报数据显示，该股实现营业收入14.00亿港元，净利润9,309.90万港元，每股收益0.16港元，毛利7.53亿港元，市盈率9.61倍。李氏大药厂股票所在的药品行业中，整体涨幅为0.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724095141971af164&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724095141971af164&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1587","00950","BK1583","BK1574","06622"],"gpt_icon":0},{"id":"2554156738","title":"【IPO前哨】业绩连亏、现金流吃紧！景泽生物赴港IPO赌未来？","url":"https://stock-news.laohu8.com/highlight/detail?id=2554156738","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554156738?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 09:50","pubTimestamp":1753321856,"startTime":"0","endTime":"0","summary":"近期，景泽生物医药（合肥）股份有限公司（简称“景泽生物”）拟通过第18A章登陆港股市场主板，由中金公司和国元国际担任此次IPO的联席保荐人。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202507_1/2bbf7c6c-867f-472a-b1b3-7a8945e77d8c.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202507_1/2bbf7c6c-867f-472a-b1b3-7a8945e77d8c.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/688191805a7712fb6314c770","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["06996","BK1574","BK1583","02142","06990","BK1191","01167","BK1161","01228","LU0196878994.USD"],"gpt_icon":0},{"id":"2553222300","title":"港股异动 | 云顶新耀(01952)涨超3% EVM14临床试验申请获受理 为自研mRNA平台首个实现“中美双报”产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2553222300","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553222300?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 09:48","pubTimestamp":1753321723,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀涨超3%，截至发稿，涨3.54%，报73.2港元，成交额1.15亿港元。消息面上，7月15日，云顶新耀宣布，其通用型的现货肿瘤治疗性疫苗EVM14注射液的新药临床试验申请获国家药品监督管理局药品审评中心的正式受理。作为云顶新耀首款自研mRNA肿瘤治疗性疫苗，EVM14在临床前研究中展现出巨大治疗潜力。同时，EVM14还能够诱导免疫记忆，展现出有效降低肿瘤复发及转移的能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK1161","BK1576","BK1574","BK1141","BK1583","03347"],"gpt_icon":0},{"id":"2553222442","title":"心通医疗-B盘中异动 早盘股价大涨5.69%报1.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553222442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553222442?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 09:44","pubTimestamp":1753321471,"startTime":"0","endTime":"0","summary":"2025年07月24日早盘09时44分，心通医疗-B股票出现异动，股价大幅上涨5.69%。截至发稿，该股报1.300港元/股，成交量223.2万股，换手率0.09%，振幅5.69%。资金方面，该股资金流入215.274万港元，流出49.596万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。其相关个股中，微创医疗、心通医疗-B、智云健康涨幅较大，振幅较大的相关个股有微创医疗、微创机器人-B、心通医疗-B，振幅分别为9.38%、6.81%、5.69%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724094431971aede0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724094431971aede0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02160","BK1574","BK1100","BK1583"],"gpt_icon":0},{"id":"2553222884","title":"港股异动 | 康方生物(09926)早盘涨超5% 依沃西疗法一线治疗胰腺癌III期临床研究完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2553222884","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553222884?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 09:42","pubTimestamp":1753321362,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物早盘涨超5%，截至发稿，涨3.84%，报148.9港元，成交额5.25亿港元。消息面上，康方生物宣布，自主研发的全球首创PD-1/VEGF双特异性抗体新药依沃西联合化疗联合/不联合莱法利用于一线转移性胰腺癌的关键/注册性III期研究，已完成首例患者入组。依沃西联合化疗联合/不联合莱法利有望填补治疗转移性胰腺癌一线免疫疗法的空白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","LU0417516571.SGD","BK1574","IE00B5MMRT66.SGD","LU2488822045.USD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348783233.USD","LU0348784397.USD","09926","LU1720050803.USD","BK1161","IE00BPRC5H50.USD","III"],"gpt_icon":0},{"id":"2553224264","title":"中国抗体-B盘中异动 早盘快速拉升5.56%报2.660港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553224264","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553224264?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 09:41","pubTimestamp":1753321260,"startTime":"0","endTime":"0","summary":"2025年07月24日早盘09时41分，中国抗体-B股票出现异动，股价快速拉升5.56%。中国抗体-B股票所在的生物技术行业中，整体涨幅为0.77%。该信息摘要如下：中国抗体-b涨超8%，截至发稿，涨8.68%，报2.63港元，成交额3173.05万港元。消息面上，中国抗体-b发布公告，于2025年7月22日，公司与23名认购人订立23份认购协议，公司有条件同意发行而认购人有条件同意认购合共1.82亿股新股份，认购价为每股认购股份2.03港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724094101a4601e9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724094101a4601e9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","03681","BK1161"],"gpt_icon":0},{"id":"2553227760","title":"康方生物盘中异动 早盘大幅上涨3.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553227760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553227760?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 09:30","pubTimestamp":1753320636,"startTime":"0","endTime":"0","summary":"2025年07月24日早盘09时30分，康方生物股票出现波动，股价快速拉升3.00%。截至发稿，该股报147.700港元/股，成交量58.8万股，换手率0.07%，振幅1.67%。康方生物股票所在的生物技术行业中，整体涨幅为0.93%。其相关个股中，圣诺医药-B、奥星生命科技、云顶新耀涨幅较大，振幅较大的相关个股有圣诺医药-B、三叶草生物-B、君实生物，振幅分别为3.56%、3.45%、2.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724093036971ae6d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724093036971ae6d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1794554557.SGD","LU0417516571.SGD","09926","IE00B543WZ88.USD","BK1574","LU0348784397.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU0348783233.USD","BK1161","IE00B5MMRT66.SGD","LU1720050803.USD"],"gpt_icon":0},{"id":"1197466032","title":"港股开盘｜恒指低开0.04%，科指低开0.26%！创新药概念股普涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1197466032","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197466032?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 09:21","pubTimestamp":1753320093,"startTime":"0","endTime":"0","summary":"7月24日，港股开盘，恒指开跌0.04%，科指开跌0.26%；科网股部分下跌，网易、百度跌超1%；创新药概念普遍走强，康方生物涨逾2%；雅江水电概念企稳，西部水泥涨近9%，上半年业绩大幅预增。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","HSTECH","BK1161","BK4614","HSI"],"gpt_icon":0},{"id":"2553670226","title":"再鼎医药获Wellington Management Group LLP增持439.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553670226","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553670226?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 07:38","pubTimestamp":1753313880,"startTime":"0","endTime":"0","summary":"格隆汇7月24日丨根据联交所最新权益披露资料显示，2025年7月21日，再鼎医药(09688.HK)获Wellington Management Group LLP在场内以每股均价27.2805港元增持439.85万股，涉资约1.2亿港元。增持后，Wellington Management Group LLP最新持股数目为5816.531万股，持股比例由4.84%上升至5.24%。追加内容本文作者可以追加内容哦 !","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724073946a6be5390&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724073946a6be5390&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","ZLAB","BK1161","BK1588","LU2488822045.USD","09688"],"gpt_icon":0},{"id":"2553060225","title":"泰坦科技拟5585万元收购境外公司ASL；美中嘉和拟配股融资2.7亿港元丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2553060225","media":"每日经济新闻","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553060225?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 07:07","pubTimestamp":1753312039,"startTime":"0","endTime":"0","summary":"丨2025年7月24日星期四丨NO.1泰坦科技拟5585万元收购境外公司ASL7月23日，泰坦科技公告称，拟使用自有或自筹资金约5585万元，收购中央硝子株式会社持有的ApolloScientificLtd.（以下简称“ASL”）100%的股权。ASL作为英国化学品制造商，拥有较为丰富的产品类别，能为客户提供超过10万种化合物，涵盖中间体构建块、氟化物和生命科学试剂等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507243465755828.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507243465755828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1515","BK1161","BK1209","02453","BK1574"],"gpt_icon":0},{"id":"2553922531","title":"开拓药业-B(09939)：KX- 826 酊1.0%治疗中国成年男性雄激素脱发关键性临床试验II期阶段达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2553922531","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553922531?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 06:15","pubTimestamp":1753308950,"startTime":"0","endTime":"0","summary":"智通财经APP讯，开拓药业-B 公布，其自主研发、潜在同类首创的 KX-826 酊 1.0%治疗脱发的关键性临床试验 II 期阶段已获得顶线数据。该项关键性临床试验是一项多中心、随机、双盲、赋形剂对照的 II/III 期适应性设计研究，用以评估 KX-826 酊 1.0%和 0.5%外用治疗中国成年男性 AGA 患者的有效性和安全性。与安慰剂组相比，0.5% BID组和 1.0% BID 组均显示出统计学显著的 疗效优势及临床意义 。KX-826 酊在临床试验显示出令人满意的安全性和耐受性，整体不良事件发生率低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","03347","BK1161","BK1583","BK1141","BK1515","09939","BK1576"],"gpt_icon":0},{"id":"2553223077","title":"加科思-B(01167)获一致行动人士进一步增持24万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553223077","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553223077?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 06:08","pubTimestamp":1753308524,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)公布，于2025年7月21日至7月22日，公司一致行动人士已于公开市场按7.05港元的平均每股价格继续买入合计24万股公司股份。紧随此次持股增加之后，截至本公告日期，一致行动人士共持有公司200,694,385股股份，约占公司已发行股份总数的25.35%。上述一致行动人士成员表示对公司的整体发展前景、增长潜力及其股份的长期投资价值充满信心。在遵守适用法律及监管规定的前提下，并不排除其可能适时进一步增持公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2553223919","title":"特朗普将自行决定5500亿美元日本对美投资的使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2553223919","media":"Odaily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553223919?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 05:23","pubTimestamp":1753305797,"startTime":"0","endTime":"0","summary":"Odaily星球日报讯 白宫新闻秘书卡罗琳·莱维特表示，总统特朗普将自行决定日本 5500 亿美元对美投资的使用。她表示，日本的投资是美日贸易协议的一部分。莱维特表示，特朗普将把这一投资用于能源、半导体、关键矿产、制药和造船等关键行业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.odaily.news/newsflash/440311?source=share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"odaily_live","symbols":["BK1574","01477","159945","159582","BK1191"],"gpt_icon":0},{"id":"2553458742","title":"“V型”反转中的基金“巨子”们","url":"https://stock-news.laohu8.com/highlight/detail?id=2553458742","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553458742?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 21:35","pubTimestamp":1753277713,"startTime":"0","endTime":"0","summary":"明星基金批量逆袭","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/73bc6b27-c783-4e6e-a0db-2f4b73c36b23.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/73bc6b27-c783-4e6e-a0db-2f4b73c36b23.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3751740","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3751740","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["09939","BK1515","BK1574","BK1161","06978"],"gpt_icon":0}],"pageSize":20,"totalPage":32,"pageCount":8,"totalSize":640,"code":"91000000","status":"200"}]}}